{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:14:08Z","timestamp":1789456448066,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the management of type 2 diabetes mellitus (T2DM) due to their survival benefits. However, these agents are associated with increases in hemoglobin (Hgb) and hematocrit (Hct), raising concern for secondary polycythemia or erythrocytosis and potential thrombotic risk. The clinical significance of these hematologic changes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed, Scopus, and Embase were searched up to February 2026 for studies evaluating the effect of SGLT2 inhibitors on hematologic parameters in adults with T2DM. Patients with primary polycythemia, end-stage renal disease (ESRD), or heart failure were excluded. Primary outcomes were changes in Hgb and Hct. Secondary outcomes included the incidence of erythrocytosis\/polycythemia and thrombotic events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 10 studies met inclusion criteria, comprising randomized and observational studies, with follow-up ranging from 8 weeks to 24 months. SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, were consistently associated with increases in Hgb and Hct. Across three randomized controlled trials, SGLT2 inhibitors significantly increased hematocrit (3 studies, 171 patients, pooled mean difference\u2009+\u20092.29%, 95% CI 1.48 to 3.09) and hemoglobin (3 studies, 171 patients, pooled mean difference\u2009+\u20090.51\u00a0g\/dL, 95% CI 0.28 to 0.74) compared with placebo. Real-world data (9,646 patients) reported an increase in polycythemia prevalence from 2.4% to 9.7%, with severe cases in 1.4% of patients. Limited data suggested a potential association with thrombotic events, with one observational study of 100 patients with JAK2-unmutated erythrocytosis reporting a 10% event rate. Hematologic changes were observed early after treatment initiation and appeared reversible following drug discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with type 2 diabetes, ESRD, or heart failure, SGLT2 inhibitor use is associated with consistent increases in hemoglobin and hematocrit. Although these effects may contribute to cardiovascular benefit, a subset of patients may develop clinically significant erythrocytosis. Clinicians should be aware of this potential effect and monitor high-risk individuals. Larger prospective studies are needed to better define the clinical significance of these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04160-1","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:46:45Z","timestamp":1786589205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-433X","authenticated-orcid":false,"given":"Elrazi Awadelkarim Hamid","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8288-8368","authenticated-orcid":false,"given":"Marrita","family":"Rabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2766-8943","authenticated-orcid":false,"given":"Ruba Adel","family":"Aweer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-2891","authenticated-orcid":false,"given":"Eihab","family":"Subahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-5740","authenticated-orcid":false,"given":"Elabbass A","family":"Abdelmahmuod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-8455","authenticated-orcid":false,"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4712-0590","authenticated-orcid":false,"given":"Mohamed Fawzi","family":"Mudarres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-7649","authenticated-orcid":false,"given":"Usra","family":"Elshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6118-3988","authenticated-orcid":false,"given":"Shehab","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"4160_CR1","doi-asserted-by":"publisher","unstructured":"Shah SR et al (2018) Sep., Canagliflozin and Cardiovascular disease- results of the CANVAS trial, Journal of Community Hospital Internal Medicine Perspectives, vol. 8, no. 5, pp. 267\u2013268. https:\/\/doi.org\/10.1080\/20009666.2018.1521245","DOI":"10.1080\/20009666.2018.1521245"},{"key":"4160_CR2","doi-asserted-by":"publisher","unstructured":"Zinman B et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, N Engl J Med, vol. 373, no. 22, pp. 2117\u20132128, Nov. https:\/\/doi.org\/10.1056\/NEJMoa1504720","DOI":"10.1056\/NEJMoa1504720"},{"key":"4160_CR3","doi-asserted-by":"publisher","unstructured":"Ekanayake P, Mudaliar S (Feb. 2023) Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr 17(2):102702. https:\/\/doi.org\/10.1016\/j.dsx.2022.102702","DOI":"10.1016\/j.dsx.2022.102702"},{"key":"4160_CR4","doi-asserted-by":"publisher","unstructured":"Mazer CD et al (2020) Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease, Circulation, vol. 141, no. 8, pp. 704\u2013707, Feb. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044235","DOI":"10.1161\/CIRCULATIONAHA.119.044235"},{"key":"4160_CR5","unstructured":"Secondary Polycythemia - StatPearls - NCBI Bookshelf. Accessed: Mar. 29, 2026. [Online]. Available: https:\/\/www-ncbi-nlm-nih-gov.qulib.idm.oclc.org\/books\/NBK562233\/"},{"key":"4160_CR6","doi-asserted-by":"publisher","unstructured":"McMullin MF et al (2019) A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline, Br J Haematol, vol. 184, no. 2, pp. 176\u2013191, Jan. https:\/\/doi.org\/10.1111\/bjh.15648","DOI":"10.1111\/bjh.15648"},{"key":"4160_CR7","doi-asserted-by":"publisher","unstructured":"Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A (2021) JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy, Blood, vol. 138, no. 26, pp. 2886\u20132889, Dec. https:\/\/doi.org\/10.1182\/blood.2021013996","DOI":"10.1182\/blood.2021013996"},{"key":"4160_CR8","doi-asserted-by":"publisher","unstructured":"Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A (Apr. 2020) Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases. Diabetes Res Clin Pract 162:108127. https:\/\/doi.org\/10.1016\/j.diabres.2020.108127","DOI":"10.1016\/j.diabres.2020.108127"},{"key":"4160_CR9","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, vol. 372, p. n71, Mar. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"4160_CR10","doi-asserted-by":"publisher","unstructured":"Arber DA et al (May 2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","DOI":"10.1182\/blood-2016-03-643544"},{"key":"4160_CR11","doi-asserted-by":"publisher","unstructured":"McMullin MF (Oct. 2016) Investigation and Management of Erythrocytosis. Curr Hematol Malig Rep 11(5):342\u2013347. https:\/\/doi.org\/10.1007\/s11899-016-0334-1","DOI":"10.1007\/s11899-016-0334-1"},{"key":"4160_CR12","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (Dec. 2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"4160_CR13","doi-asserted-by":"publisher","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ, p. l4898, Aug. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4160_CR14","doi-asserted-by":"publisher","unstructured":"Gualdi-Russo E, Zaccagni L (Mar. 2026) The Newcastle\u2013Ottawa Scale for Assessing the Quality of Studies in Systematic Reviews. Publications 14(1). https:\/\/doi.org\/10.3390\/publications14010004","DOI":"10.3390\/publications14010004"},{"key":"4160_CR15","doi-asserted-by":"publisher","unstructured":"Barker TH et al (2025) The revised JBI critical appraisal tool for the assessment of risk of bias for cohort studies, JBI Evidence Synthesis, vol. 23, no. 3, pp. 441\u2013453, Mar. https:\/\/doi.org\/10.11124\/JBIES-24-00103","DOI":"10.11124\/JBIES-24-00103"},{"key":"4160_CR16","doi-asserted-by":"publisher","unstructured":"Ghanim H et al (2020) Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis, J Clin Endocrinol Metab, vol. 105, no. 4, p. dgaa057, Apr. https:\/\/doi.org\/10.1210\/clinem\/dgaa057","DOI":"10.1210\/clinem\/dgaa057"},{"key":"4160_CR17","doi-asserted-by":"publisher","unstructured":"Karag\u00fcn B, Bak\u0131ner OS (2024) Tip 2 Diyabetli Hastalarda SGLT2 \u0130nhibit\u00f6rlerinin Hematolojik Parametreler \u00dczerindeki Etkileri: Retrospektif Bir \u00c7al\u0131\u015fma, Turk J Diab Obes, vol. 8, no. 2, pp. 154\u2013162, Aug. https:\/\/doi.org\/10.25048\/tudod.1510532","DOI":"10.25048\/tudod.1510532"},{"key":"4160_CR18","doi-asserted-by":"publisher","unstructured":"Thiele K et al (2021) Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study, Diabetes Obes Metab, vol. 23, no. 12, pp. 2814\u20132818, Dec. https:\/\/doi.org\/10.1111\/dom.14517","DOI":"10.1111\/dom.14517"},{"key":"4160_CR19","doi-asserted-by":"publisher","unstructured":"Gosmanov AR, Gemoets DE, Schumacher KA (2024) Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy, J Endocrinol Invest, vol. 47, no. 10, pp. 2615\u20132621, Mar. https:\/\/doi.org\/10.1007\/s40618-024-02350-1","DOI":"10.1007\/s40618-024-02350-1"},{"key":"4160_CR20","doi-asserted-by":"publisher","unstructured":"Schwarz Y, Klein P, Lev-Shalem L (2023) Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study, Acta Diabetol, vol. 61, no. 1, pp. 99\u2013105, Sep. https:\/\/doi.org\/10.1007\/s00592-023-02174-0","DOI":"10.1007\/s00592-023-02174-0"},{"key":"4160_CR21","doi-asserted-by":"publisher","unstructured":"Gangat N et al (Jul. 2023) Sodium-glucose co\u2010transporter\u20102 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases. Am J Hematol 98(7). https:\/\/doi.org\/10.1002\/ajh.26933","DOI":"10.1002\/ajh.26933"},{"key":"4160_CR22","doi-asserted-by":"publisher","unstructured":"Heerspink HJL et al (2020) Dapagliflozin in Patients with Chronic Kidney Disease, N Engl J Med, vol. 383, no. 15, pp. 1436\u20131446, Oct. https:\/\/doi.org\/10.1056\/NEJMoa2024816","DOI":"10.1056\/NEJMoa2024816"},{"key":"4160_CR23","doi-asserted-by":"publisher","unstructured":"Sano M, Goto S (Apr. 2019) Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation 139:1985\u20131987. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038881","DOI":"10.1161\/CIRCULATIONAHA.118.038881"},{"key":"4160_CR24","doi-asserted-by":"publisher","unstructured":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure | New England Journal of Medicine. Accessed: Jul. 01, 2026. [Online]. Available: https:\/\/www-nejm-org.qulib.idm.oclc.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2022190","DOI":"10.1056\/NEJMoa2022190"},{"key":"4160_CR25","doi-asserted-by":"publisher","unstructured":"Van Raalte DH et al (2019) The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes, Diabetes Care, vol. 42, no. 10, pp. 1921\u20131929, Oct. https:\/\/doi.org\/10.2337\/dc19-0937","DOI":"10.2337\/dc19-0937"},{"key":"4160_CR26","doi-asserted-by":"publisher","DOI":"10.4274\/haseki.galenos.2025.14633","author":"E Hoca","year":"2025","unstructured":"Hoca E, Kalayci N (2025) The Impact of SGLT2 Inhibitors on Hemoglobin Levels in Type 2 Diabetes: Potential Benefits Beyond Glycemic and Renal Outcomes. Haseki Aug. https:\/\/doi.org\/10.4274\/haseki.galenos.2025.14633","journal-title":"Haseki Aug"},{"issue":"22","key":"4160_CR27","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.2169\/internalmedicine.55.6367","volume":"55","author":"S Hirose","year":"2016","unstructured":"Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y (2016) Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus. Intern Med 55(22):3239\u20133245. https:\/\/doi.org\/10.2169\/internalmedicine.55.6367","journal-title":"Intern Med"},{"key":"4160_CR28","doi-asserted-by":"publisher","unstructured":"Tefferi A, Barbui T (2020) Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management, Am J Hematol, vol. 95, no. 12, pp. 1599\u20131613, Dec. https:\/\/doi.org\/10.1002\/ajh.26008","DOI":"10.1002\/ajh.26008"},{"key":"4160_CR29","doi-asserted-by":"publisher","unstructured":"Spivak JL (Dec. 2002) Polycythemia vera: myths, mechanisms, and management. Blood 100(13):4272\u20134290. https:\/\/doi.org\/10.1182\/blood-2001-12-0349","DOI":"10.1182\/blood-2001-12-0349"},{"key":"4160_CR30","doi-asserted-by":"publisher","unstructured":"Tian Q, Guo K, Deng J, Zhong Y, Yang L (Jan. 2022) Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. J Cell Mol Med 26(2):540\u2013547. https:\/\/doi.org\/10.1111\/jcmm.17115","DOI":"10.1111\/jcmm.17115"},{"key":"4160_CR31","doi-asserted-by":"publisher","unstructured":"Abdulgayoom M, Alshurafa A, Kaddoura R, Al-Mashdali AF, Mohamed SF, Yassin MA Anemia of Chronic Disease Revisited: Hepcidin Dysregulation, Erythropoietic Failure, and Emerging Roles of SGLT2 Inhibition, European Journal of Haematology, vol. n\/a, no. n\/a. https:\/\/doi.org\/10.1111\/ejh.70197","DOI":"10.1111\/ejh.70197"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04160-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04160-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:42Z","timestamp":1789454862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04160-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4160"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04160-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the University of Louisville Institutional Review Board (IRB) with approval number 23.0545All authors have no conflict of interest.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"232"}}